Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Pax Neuroscience Inc
Profile last edited on: 12/4/19      CAGE: 5KG00      UEI: NK9NKGBFTCF3

Business Identifier: Protein biomarkers
Year Founded
2009
First Award
2013
Latest Award
2018
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1113 Juniper Terrace
Glenview, IL 60025
   (847) 998-6883
   N/A
   www.paxneuroscience.com
Location: Single
Congr. District: 09
County: Cook

Public Profile

Anchored in work exclusively licensed from University of Illinois. Pax Neuroscience Inc. (“Pax”) is a life sciences company structured around protein biomarker-based clinical laboratory services and products that address unmet needs in the fields of Neuroscience and Psychiatry. Engaging technology addressing antidepressant drug development and blood tests for depression diagnosis and treatment efficacy, Pax Neuroscience Inc. (“Pax”) is focused on the development of biomarker assays to inform patient and clinician decisions and to offer services to Pharma companies to improve research and development of new and better antidepressants and other agents that may offer antidepressant act

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
2
Conversion Rate
100.00%
Phase I Dollars
$743,620
Phase II Dollars
$821,308
Total Awarded
$1,564,928

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 2 NIH $871,346
Project Title: Using a novel model of antidepressant efficacy to discover new compounds and personalized treatments.
2014 2 NIH $693,582
Project Title: A Peripheral Diagnostic Biomarker for Major Depressive Disorder

Key People / Management

  Mark Rasenick -- Co-Founder, President, Chief Technology Officer

  Debra Bass -- Co-Founder, Chief Executive Officer

  Paul Billings -- Founding Member, Director

  Lee Schechter

  Helene J Shambelan

Company News

There are no news available.